Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Alagebrium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alagebrium SCHEMBL1820212 | 0.98 | KMT2A (0.71) | KMT2APOLBOPRM1OPRD1MAPT | |
| Alagebrium SCHEMBL1648822 | 0.97 | KMT2A (0.74) | KMT2APOLBOPRM1OPRD1MAPT | |
| Bromide SCHEMBL3854076 | 0.88 | KMT2A (0.71) | KMT2APOLBOPRM1OPRD1MAPT | |
| SCHEMBL6535467 | 0.84 | KMT2A (0.74) | KMT2APOLBOPRM1OPRD1MAPT | |
| Hydrochloric Acid SCHEMBL3846706 | 0.84 | OPRM1 (0.57) | KMT2APOLBOPRM1OPRD1MAPT | |
| Bromide SCHEMBL3845600 | 0.83 | KMT2A (0.76) | KMT2APOLBOPRM1OPRD1MAPT | |
| Bromide SCHEMBL5004646 | 0.83 | KMT2A (0.76) | KMT2APOLBOPRM1OPRD1MAPT | |
| SCHEMBL6938197 | 0.83 | KMT2A (0.97) | KMT2APOLBOPRM1OPRD1MAPT | |
| SCHEMBL6535048 | 0.82 | KMT2A (0.59) | KMT2APOLBOPRM1OPRD1MAPT | |
| Bromide SCHEMBL5004644 | 0.82 | KMT2A (0.74) | KMT2APOLBOPRM1OPRD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 858 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122328-A1 | COMPOSITIONS AND METHODS FOR VASCULAR STABILIZATION | BARD PERIPHERAL VASCULAR, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| US-20250034413-A1 | METHODS FOR DECELLULARIZING ANIMAL TISSUE AND BIOINKS DERIVED THEREFROM | VIRGINIA COMMONWEALTH UNIVERSITY | 2025-01-30 | — | — | US | claimed |
| US-20250025048-A1 | Liver Viscoelastic Changes and Biomarkers for Cancer Invasion | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-01-23 | — | — | US | claimed |
| WO-2025012705-A2 | INHIBITING WEIGHT GAIN AND THE RELATED MUSCLE STRUCTURAL, FUNCTIONAL AND PERFORMANCE DETERIORATION INDUCED BY IMBALANCED DIET | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-01-16 | — | — | WO | claimed |
| CN-118903117-A | Application of ALT711 in preparation of medicines for preventing and treating inflammatory bowel disease | 浙江大学医学院附属第一医院(浙江省第一医院) | 2024-11-08 | — | — | CN | claimed |
| EP-4440440-A1 | LIVER VISCOELASTIC CHANGES AND BIOMARKERS FOR CANCER INVASION | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2024-10-09 | — | — | EP | claimed |
| WO-2024145644-A2 | TREATMENT OF IMMUNOLOGICALLY COLD SOLID TUMORS | CANTEX PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| WO-2024144816-A1 | TREATMENT OF IMMUNOLOGICALLY COLD SOLID TUMORS | CANTEX PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| WO-2023107410-A1 | METHODS FOR DECELLULARIZING ANIMAL TISSUE AND BIOINKS DERIVED THEREFROM | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2023102546-A1 | LIVER VISCOELASTIC CHANGES AND BIOMARKERS FOR CANCER INVASION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-06-08 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20070099966-A1 | Device and Method for Inhibiting AGE Complex Formation | Cell Viable Corporation | 2007-05-03 | — | — | US | claimed |
| WO-2007044309-A2 | DEVICE AND METHOD FOR INHIBITING AGE COMPLEX FORMATION | VASIX CORPORATION (US) | 2007-04-19 | — | — | WO | claimed |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | SYNVISTA THERAPEUTICS, INC. | 2007-02-01 | — | — | US | claimed |
| US-7022719-B2 | Preventing and reversing the formation of advance glycosylation endproducts | ALTEON, INC. (US) | 2006-04-04 | — | — | US | claimed |
| EP-1592435-A1 | OPHTHALMIC FORMULATION FOR THE PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Chakshu Research, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | claimed |
| US-20040137068-A1 | Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye | LIVIONEX INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004058289-A1 | OPHTHALMIC FORMULATION FOR THE PREVENTION AND TREATMENT OF OCULAR CONDITIONS | CHAKSHU RESEARCH, INC. (US) | 2004-07-15 | — | — | WO | claimed |
| US-20040034074-A1 | Preventing and reversing the formation of advance glycosylation endproducts | SYNVISTA THERAPEUTICS, INC. | 2004-02-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | KMT2A 4599/4885POLB 2072/4885OPRM1 3301/4885 |
| US-20040034074-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | KMT2A 3689/4885POLB 2423/4885OPRM1 4869/4885 |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | KMT2A 3689/4885POLB 2423/4885OPRM1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.